Oral Antineoplastic Agents: Assessing the Delay in Care

Table 2

Characteristics of 58 patients.

Covariant	Days to receipt
		Mean	SD
Gender
Male	32	8.28	8.98	0.07
Female	26	10.54	6.33
Age (year)
<60	25	9.48	6.92	0.97
≥60	33	9.15	8.70
Medication prescribed
Pomalidomide	7	5.86	3.58	0.03
Lenalidomide	6	4.83	2.32
Temozolomide	11	7.45	3.11
Capecitabine	16	14.06	12.31
Others	18	9.00	5.39
REMS
Yes	15	6.07	3.56	0.02
No	43	10.42	8.71
Insurance
Private	23	10.74	6.28	0.003
Medicaid	8	6.88	5.94
Medicare AB	11	13.09	13.66
Medicare D	15	5.67	3.15
No insurance	1	8.00	n/a
Secondary insurance
Yes	9	8.00	3.46	0.94
No	49	9.53	8.49
Cost to patient
No costs	31	8.97	9.40	0.22
Some costs	27	9.67	5.92
Patient assistance program use
Yes	21	10.43	10.98	0.85
No	37	8.65	5.57
PA required
Yes	37	9.70	9.13	0.99
No	21	8.57	5.26

value was calculated by excluding one patient without insurance.